Online inquiry

IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5584MR)

This product GTTS-WQ5584MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Asthma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5584MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2866MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ6267MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ14629MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ15362MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ13431MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ7003MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ7392MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ4169MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754111
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW